Elena Conti, MD, PhD

Graduated in medicine-1994. Specialized in Cardiology-1998. PhD in Molecular and Cellular cardiology-2003, working on the subject of IGF-1 and myocardial infarction. European Accreditation in Intensive Cardiac Care-Paris-October 2008. Master’s degree in Clinical Competence in Cardiac Intensive Care-Florence University-2010. Thereafter research less than part-time, jointly with ward duties, into acute coronary syndromes and growth factors in vascular disease biology. Works and investigates in the field of diabetes, atherothrombosis, acute coronary syndromes, national and international surveys, such as- EYESHOT investigation. Focus in research-2010: role of growth factor deficiency in atherothrombosis and hypertensive disease, amyotrophic lateral sclerosis, or cancer with eye disease in patients treated with targeted drugs. Projects proposed to French industries, such as Ipsen-2011. Recent interest in Sars-Cov2-related manifestations, & related thrombotic or hypertensive risk. More work dedicated to the dramatic eminent infestation multiplier of Sars-CoV-2 affection, cysticercosis by Taenia larvae, known to medicine since decades, and outblown in two peaks in the recent fifty years, due to HIV first and Sars-CoV-2 epidemics-pandemics thereafter. Graduated in medicine-1994. Specialized in Cardiology-1998. PhD in Molecular and Cellular cardiology-2003, working on the subject of IGF-1 and myocardial infarction. European Accreditation in Intensive Cardiac Care-Paris-October 2008. Master’s degree in Clinical Competence in Cardiac Intensive Care-Florence University-2010. Thereafter research less than part-time, jointly with ward duties, into acute coronary syndromes and growth factors in vascular disease biology. Works and investigates in the field of diabetes, atherothrombosis, acute coronary syndromes, national and international surveys, such as- EYESHOT investigation. Focus in research-2010: role of growth factor deficiency in atherothrombosis and hypertensive disease, amyotrophic lateral sclerosis, or cancer with eye disease in patients treated with targeted drugs. Projects proposed to French industries, such as Ipsen-2011. Recent interest in Sars-Cov2-related manifestations, & related thrombotic or hypertensive risk. More work dedicated to the dramatic eminent infestation multiplier of Sars-CoV-2 affection, cysticercosis by Taenia larvae, known to medicine since decades, and outblown in two peaks in the recent fifty years, due to HIV first and Sars-CoV-2 epidemics-pandemics thereafter.